Sanofi-aventis Expands its Early-Stage Pipeline
By Heather Cartwright
Pharma Deals Review: Vol 2010 Issue 7 (Table of Contents)
Published: 21 Sep-2010
DOI: 10.3833/pdr.v2010.i7.1377 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Sanofi-aventis has acquired rights to Ascenta Therapeutics’ early-stage oral cancer drug candidates while its Sanofi Pasteur vaccine division has signed a partnership with the French biotech Vivalis for the development of human monoclonal antibodies against various infectious diseases...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS